CompletedNot Applicable

Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection

United States110 participantsStarted 2018-09-14

Plain-language summary

This is a multi-center prospective study designed to collect blood samples from transplant patients in order to improve Natera's method for determining allograft rejection status using the donor-derived cell-free DNA analysis, called Prospera.

Who can participate

Age range2 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subject must be 2 years old or older at the time of enrollment * Subject or Legally Authorized Representative is willing and able to sign the informed consent form (and assent form, if applicable), prior to participation in any study-related procedures. * Subject has received at least one organ transplant prior to enrollment. Exclusion Criteria: * Pediatric subjects under 2 years old * Subject received donor organ from an identical twin

What they're measuring

To develop an assay to detect allograft rejection status in transplant patients involving amplification of donor-derived cell-free DNA from donor recipient blood.

Timeframe: 1-3 years

Trial details

NCT IDNCT03984747

SponsorNatera, Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-08-23

View on ClinicalTrials.gov More Transplant Rejection trials